[go: up one dir, main page]

WO1999026660A3 - Produit a activite proliferative utile pour traiter des cellules proliferatives - Google Patents

Produit a activite proliferative utile pour traiter des cellules proliferatives Download PDF

Info

Publication number
WO1999026660A3
WO1999026660A3 PCT/GB1998/003509 GB9803509W WO9926660A3 WO 1999026660 A3 WO1999026660 A3 WO 1999026660A3 GB 9803509 W GB9803509 W GB 9803509W WO 9926660 A3 WO9926660 A3 WO 9926660A3
Authority
WO
WIPO (PCT)
Prior art keywords
proliferation
active
proliferating cells
drugs
conjugates
Prior art date
Application number
PCT/GB1998/003509
Other languages
English (en)
Other versions
WO1999026660A2 (fr
Inventor
Christopher Ralph Franks
Bitta Ruggero Della
Original Assignee
Bioinnovation Ltd
Christopher Ralph Franks
Bitta Ruggero Della
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinnovation Ltd, Christopher Ralph Franks, Bitta Ruggero Della filed Critical Bioinnovation Ltd
Priority to EP98955771A priority Critical patent/EP1032427A2/fr
Priority to NZ504625A priority patent/NZ504625A/xx
Priority to AU12499/99A priority patent/AU1249999A/en
Priority to JP2000521861A priority patent/JP2001523731A/ja
Priority to CA002311733A priority patent/CA2311733A1/fr
Publication of WO1999026660A2 publication Critical patent/WO1999026660A2/fr
Publication of WO1999026660A3 publication Critical patent/WO1999026660A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

On décrit un produit comprenant une fraction proliférative active, plus spécifiquement une cytokine ou un facteur de croissance ayant un récepteur à haute affinité, qui est lié(e) à un agent biologiquement actif qui lui-même affecte préférentiellement ou sélectivement des cellules prolifératives. Un promoteur de prolifération actif, par exemple une interleukine active IL-2, est utilisé avec profit pour apporter des espèces intéressantes du point de vue pharmacologique à des cellules dont la prolifération n'est pas désirée. Par exemple, certains médicaments de l'invention régulent ou inhibent la prolifération à l'aide d'une molécule qui contient un promoteur actif de prolifération. L'agent biologiquement actif est généralement sélectionné dans le groupe constitué par des médicaments antiprolifératifs, des composés qui interfèrent avec la synthèse nucléotidique, des radio-isotopes, des séquences de gènes et des séquences nucléotidiques antisens.
PCT/GB1998/003509 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives WO1999026660A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98955771A EP1032427A2 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives
NZ504625A NZ504625A (en) 1997-11-26 1998-11-25 Cytokines or growth factors linked to agents which control cell proliferation and pharmaceutical use
AU12499/99A AU1249999A (en) 1997-11-26 1998-11-25 Proliferatively active product for treating proliferating cells
JP2000521861A JP2001523731A (ja) 1997-11-26 1998-11-25 増殖している細胞を治療するための増殖活性生成物
CA002311733A CA2311733A1 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724838.9A GB9724838D0 (en) 1997-11-26 1997-11-26 Compositions
GB9724838.9 1997-11-26

Publications (2)

Publication Number Publication Date
WO1999026660A2 WO1999026660A2 (fr) 1999-06-03
WO1999026660A3 true WO1999026660A3 (fr) 1999-10-14

Family

ID=10822573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/003509 WO1999026660A2 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives

Country Status (8)

Country Link
EP (1) EP1032427A2 (fr)
JP (1) JP2001523731A (fr)
AU (1) AU1249999A (fr)
CA (1) CA2311733A1 (fr)
GB (1) GB9724838D0 (fr)
NZ (1) NZ504625A (fr)
WO (1) WO1999026660A2 (fr)
ZA (1) ZA9810759B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074724A2 (fr) * 1999-06-03 2000-12-14 Bioinnovation Limited Produits de therapie genique
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en) 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
MX347324B (es) 2011-03-11 2017-04-19 Assist Publique-Hôpitaux De Paris Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (fr) * 1987-12-02 1989-06-07 Neorx Corporation Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle
EP0398305A2 (fr) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production
EP0510949A2 (fr) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
WO1993006847A1 (fr) * 1991-10-07 1993-04-15 Genentech, Inc. Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
WO1995027732A2 (fr) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Ligands et molecules chimeriques a permutation circulaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (fr) * 1987-12-02 1989-06-07 Neorx Corporation Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle
EP0398305A2 (fr) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production
EP0510949A2 (fr) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
WO1993006847A1 (fr) * 1991-10-07 1993-04-15 Genentech, Inc. Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
WO1995027732A2 (fr) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Ligands et molecules chimeriques a permutation circulaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUKOWSKI R. M.: "Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2", CANCER, vol. 80, no. 7, 1 October 1997 (1997-10-01), pages 1198 - 1220, XP002097613 *
KONIGSBERG PJ ET AL: "The development of IL-2 conjugated liposomes for therapeutic purposes.", BIOCHIM BIOPHYS ACTA, MAR 13 1998, 1370 (2) P243-51, NETHERLANDS, XP002110538 *
MATOS DA SILVA A. C. ET AL: "Outpatient therapy with aldesleukin after autologous bone marrow transplantation", AM J. HEALTH-SYST PHARM, vol. 53, 15 July 1996 (1996-07-15), pages 1722 - 1727, XP002097614 *
Proleukin (aldesleukin) CHIRON. January 1998 Prescribing information (United States) *
SUNDIN D. J. ET AL: "Aldesleukin therapy in HIV infected patients", AM J. HEALTH-SYST PHARM, vol. 55, 15 July 1998 (1998-07-15), pages 1520 - 1523, XP002097615 *
SUTHERLAND F. ET AL: "Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin", CANCER IMMUNOL IMMUNOTHER, vol. 31, 1990, pages 312 - 320, XP002097616 *

Also Published As

Publication number Publication date
NZ504625A (en) 2002-12-20
CA2311733A1 (fr) 1999-06-03
GB9724838D0 (en) 1998-01-21
JP2001523731A (ja) 2001-11-27
EP1032427A2 (fr) 2000-09-06
ZA9810759B (en) 2000-05-25
WO1999026660A2 (fr) 1999-06-03
AU1249999A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
Ye et al. Cellular and molecular mechanisms of IFN‐γ production induced by IL‐2 and IL‐12 in a human NK cell line
WO1997020056A3 (fr) Expression de genes dans des vegetaux renforcee par des activateurs
Salkowski et al. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages
ZA96503B (en) Stable-lipid-comprising drug delivery complexes and methods for their production
HUP9801216A2 (hu) DNS-molekulák, előállításuk és génterápiában való alkalmazásuk
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
NZ597270A (en) Use of a pyrimidine nucleotide precursor for reducing side effects of a cytotoxic cancer chemotherapy agent
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
EP2058327A3 (fr) Gènes codant des récepteurs odorants d'insectes et utilisations associées
IL121421A0 (en) Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
CA2088258A1 (fr) Oligonucleotides modifies par la pyrimidine resistants a la nuclease, detectant et modulant l'expression genique
CA2315647A1 (fr) Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques aryle et heteroaryle substituees
WO1999026660A3 (fr) Produit a activite proliferative utile pour traiter des cellules proliferatives
AU2647495A (en) Novel potent inducers of terminal differentiation and methods of use thereof
AU2748701A (en) Rapamycin analogs
AU8088694A (en) 2'-amido and 2'-peptido modified oligonucleotides
IL128769A0 (en) Expression of an exogenous gene by us of a non-mammalian dna virus
EP2028274A3 (fr) Un oligonucléotide antisens dirigé contre le gène de TGF-beta2
Shockett et al. Inhibitors of poly (ADP-ribose) polymerase increase antibody class switching.
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
WO2001026629A3 (fr) Lipide cationique-neutre destine a l'apport d'acides nucleiques et de medicaments
DK0426521T3 (da) Anvendelse af interleukin 2 til behandling af leukæmi
AU4848793A (en) Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
WO1999058656A3 (fr) Liberation prolongee d'adn depuis des matrices structurales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 12499/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 504625

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2311733

Country of ref document: CA

Ref country code: CA

Ref document number: 2311733

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998955771

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998955771

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998955771

Country of ref document: EP